Evidence map›Paper›PMID 40046234›Full record

ArticleFrontiers in cell and developmental biology2025

Current advances and future prospects of cell reprogramming in progeroid syndromes.

Lucas Moledo-Nodar, Víctor Celemín-Capaldi, Alejandro P Ugalde, José M P Freije

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lucas Moledo-NodarDepartamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain.
Víctor Celemín-CapaldiDepartamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain.
Alejandro P UgaldeDepartamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain.
José M P FreijeDepartamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell reprogramming consists in the reverse process to cell differentiation, making cells lose their identity and age-related characteristics and granting an increased potential for proliferation and redifferentiation on different lineages. This process holds immense potential for the treatment of several pathologies, including progeroid syndromes, diseases that recapitulate the symptoms seen in physiological aging in an accelerated manner. Among the recent advances on the use of cell reprogramming in the context of progeroid syndromes, the interventions based on partial reprogramming, consisting on the dedifferentiation of cells only up to a point in which they lose age related characteristics but keep their identity, stand out. This partial reprogramming can be achieved both using the forced expression of transcription factors or cocktails of small molecules that regulate different biological processes. While all these advances are promising, the use of cell reprogramming in the treatment of progeroid syndromes still faces several challenges, such as the development of methods that allow for an efficient delivery of cell reprogramming factors

Indexed as

agingcell reprogrammingIPSCprogeriastem cell

Identifiers

PMID40046234
PMCPMC11880271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.